Lymphangioleiomyomatosis (LAM) Diagnostic Pathway

Enhancing Clinical Confidence Through VEGF-D Testing

LAMair™

Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung condition that predominantly affects women of reproductive age. Because its symptoms and imaging patterns overlap with many other pulmonary diseases, clinicians often face uncertainty during evaluation.[1]
Vascular endothelial growth factor-D (VEGF-D) is a well-studied biomarker associated with LAM. In patients with characteristic HRCT features, elevated VEGF-D levels may provide supportive evidence for LAM as part of a comprehensive clinical assessment.[1,2]
VEGF-D testing requires only a routine blood draw, helping clinicians strengthen their level of clinical confidence and make more informed decisions about next steps in evaluation and management.[1]

3-8 PER MILLION

women worldwide are affected by LAM[1]

VEGF-D IS ASSOCIATED WITH LAM

in published ATS/JRS guidelines[1]

PATIENTS EXPERIENCE DELAYED DIAGNOSIS

due to overlapping symptoms with other conditions [2]

9808 Medical Center Dr., Suite 330, Rockville, MD | (888) 261-2812 | LAMair@trilliumbio.com

M 35 1.0

Test Overview

Specimen Type:
Serum

Turnaround Time:
2-7 Days

Result Format:
Quantitative, pg/mL

*The biomarker (VEGF-D) was developed and its performance characteristics determined by TrilliumBiO. It has not been cleared or approved by the U.S. Food and Drug Administration. References: 1. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2017;196(10):1337–1348 2. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: LAM Diagnosis and Management. Am J Respir Crit Care Med. 2016;194(6):748–761.

Key Advantages

- Blood-based biomarker that may support clinical assessment in suspected LAM[1]
- Guideline-referenced marker included in ATS/JRS clinical practice documents[1,2]
- May help reduce the need for invasive procedures in appropriate clinical scenarios[1,2]
- Provides additional insight when imaging findings overlap with other cystic lung diseases[1,2]
- Supports more informed evaluation and management decisions[1]

9808 Medical Center Dr., Suite 330, Rockville, MD | (888) 261-2812 | LAMair@trilliumbio.com